Details of the Drug

General Information of Drug (ID: DMI7ZK3)

Drug Name
NKTT-120
Synonyms INKT mAb; Natural killer T cell antibody (asthma/COPD/Dermatitis); NKT cell antibody (asthma/COPD/Dermatitis), NKT; Natural killer T cell antibody (asthma/COPD/Dermatitis), NKT Therapeutics
Indication
Disease Entry ICD 11 Status REF
Sickle-cell disorder 3A51 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB17730
TTD ID
D0D5LX

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Immunoglobulin G1k (IgG1k) TTA6ZER NOUNIPROTAC Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01783691) Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD). U.S. National Institutes of Health.
2 Advances in Sickle Cell Therapies in the Hydroxyurea Era. Mol Med. 2014; 20(Suppl 1): S37-S42.